<DOC>
	<DOCNO>NCT02196506</DOCNO>
	<brief_summary>The purpose study assess tolerability , safety , efficacy brexpiprazole ( 2.0 mg/day ) adjunctive therapy adult subject diagnosis MDD without anxious distress</brief_summary>
	<brief_title>Study Safety Efficacy Fixed-dose Brexpiprazole ( OPC-34712 ) Adjunctive Therapy Treatment Adults With Major Depressive Disorder With Without Anxious Distress</brief_title>
	<detailed_description>The introduction atypical antipsychotic create renew interest adjunctive therapy MDD , particularly treatment-resistant MDD . Several atypical antipsychotic show enhance response ADT . This phase 3 , multicenter , randomize , double-blind , placebo-controlled , fixed-dose trial design assess safety efficacy brexpiprazole ( 2.0 mg/day ) adjunctive therapy assign open-label ADT depress subject without anxious distress .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>Male Female subject 1865 year age , diagnosis major depressive disorder without anxious distress Current depressive episode must least 8 week duration Subjects history Neuroleptic Malignant Syndrome Serotonin Syndrome Subjects report inadequate response 3 antidepressant treatment current episode Subjects current Axis I diagnosis : Delirium , dementia , amnestic cognitive disorder , Schizophrenia , schizoaffective disorder , psychotic disorder , Bipolar I II disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>OPC-34712</keyword>
	<keyword>brexpiprazole</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Adjunctive Treatment</keyword>
	<keyword>Anxious Distress</keyword>
</DOC>